2024-03-14
Realheart Awarded Almi Guldstänk as Innovator of the Year
Västerås, 14 March 2024 – Scandinavian Real Heart AB (publ) announces today that the company has been awarded Innovator of the Year 2023 in the Almi Guldstänk competition. Realheart was nominated based on the jury's motivation that highlights the company's development of the groundbreaking artificial heart Realheart TAH. After an open vote during the period 8-25 February, Realheart has been selected as the winner in the Innovation category. Representatives of Realheart were present at the ceremony on 14 March in Västerås Concert Hall to receive the award.
Guldstänk is a networking event and competition organised by Almi Mälardalen, Företagarna Västerås, Handelskammaren Mälardalen, Marknadsföreningen i Västerås and the City of Västerås to celebrate local entrepreneurs. The awards are given to reward entrepreneurs and organisations based in the region and are awarded to nominees selected by public vote.
"We are honoured to have been awarded Almi Guldstänk's Innovator of the Year award. We see this award as proof of the confidence in our hard work to fundamentally change the care for people living with heart failure", says Realheart's CEO, Ina Laura Perkins.
In Europe and the US, there are currently more than 8,300 patients with severe heart failure waiting for a heart transplant, and many unfortunately die during their time on the waiting list. Realheart is developing Realheart TAH, an artificial heart that resembles the human heart in structure and function, whose unique product characteristics provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant.
About Us
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide entirely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. Realheart TAH (Total Artificial Heart) is currently being evaluated in extensive preclinical models ahead of its first clinical study in patients expected to commence in 2025. Realheart TAH addresses a significant and urgent medical need – currently many people worldwide are on waiting lists for a heart transplant, and unfortunately, many patients die while waiting. In the future, artificial hearts may become an alternative to transplantation for broader groups of patients with severe heart failure. The company's stock is traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se
